Experience of using the domestic inhibitor IL (anti-IL-17A) in the treatment of moderate-severe psoriasis

Savvina N.A.; Sleptsova N.P.; Steshenko I.G.

doi:https://doi.org/10.17116/klinderma202019051739

Savvina N.A.

North-Eastern Federal University named after M.K. Ammosov

Sleptsova N.P.

Yakut Republican skin and venereal dispensary

Steshenko I.G.

Yakut Republican skin and venereal dispensary

Experience of using the domestic inhibitor IL (anti-IL-17A) in the treatment of moderate-severe psoriasis

Authors:

Savvina N.A., Sleptsova N.P., Steshenko I.G.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2020;19(5): 739‑748

DOI: 10.17116/klinderma202019051739

Read: 12626 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Savvina NA, Sleptsova NP, Steshenko IG. Experience of using the domestic inhibitor IL (anti-IL-17A) in the treatment of moderate-severe psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2020;19(5):739‑748. (In Russ.)
https://doi.org/10.17116/klinderma202019051739

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Psoriasis: analysis of comorbid pathology. Russian Journal of Clinical Dermatology and Venereology. 2025;(1):16-21

Search of diagnostic and prognostic biomarkers of immunoinflammatory dermatoses by means of flow cytometry. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):170-177

Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xerosis. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):178-184

Historical aspects and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):284-292

Key specific tools for assessment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):319-325

Psychodermatological aspects of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):403-411

New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):453-460

Persistence of skin process remission in patients with moderate and severe psoriasis vulgaris in application of netakimab: a five-year observational study results. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):462-468

Clinical discussion of patients with follicular occlusion syndrome and comorbid pathology. Russian Journal of Clinical Dermatology and Venereology. 2025;(5):596-603

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

Abstract:

Psoriasis is a genetically determined chronic multifactorial inflammatory systemic disease with a predominant skin lesion, characterized by impaired proliferation and differentiation of keratinocytes. For the treatment of patients with psoriasis and psoriatic arthritis in Russia, a number of genetically engineered biological drugs (GEBD) are used: tumor necrosis factor inhibitors-TNF — α (adalimumab, infliximab, etanercept, certolizumab pegol), interleukin inhibitors-IL — 12/23 (ustekinumab) and IL-17A (secukinumab, ixekizumab). In April 2019, a new Russian original IL-17A (anti-IL-17A) inhibitor netakimab (Efleira) was registered for the treatment of moderate and severe psoriasis. Netakimab is a highly humanized recombinant monoclonal antibody that binds interleukin-17A. The article provides clinical cases on therapy with a netakimab. Clinical efficacy, tolerability and possible side effects of netakimab therapy in the treatment of moderate psoriasis vulgaris who are resistant to therapy and have not previously received biological therapy are evaluated.

RESULTS

Patients have achieved rapid and stable results on netakimab therapy in relation to skin manifestations of psoriasis, psoriatic onychodystrophy and quality of life of patients. Side effects were not detected on the therapy of netakimab.

CONCLUSION

Treatment by netakimab contributes to increased patient adherence to treatment and a favorable safety profile.

Keywords:

psoriasis

biological therapy

interleukin-17A inhibitor

BCD-085

PASI 75

Authors:

Savvina N.A.

North-Eastern Federal University named after M.K. Ammosov

Sleptsova N.P.

Yakut Republican skin and venereal dispensary

Steshenko I.G.

Yakut Republican skin and venereal dispensary

Received:

03.09.2020

Accepted:

29.09.2020

Close metadata

References:

Kubanov AA, Bogdanova EV. Dermatovenereologic health care delivery management in the russian federation. results of 2018. Vestnik dermatologii i venerologii. 2019;4:8-23. (In Russ.).
Khairutdinov VR, Belousova IE, Samtsov AV. Immune pathogenesis of psoriasis. Vestnik dermatologii i venerologii. 2016;4:20-26. (In Russ.).
Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993-1005.
Bakulev AL. Strategy «treat to target» for patients with psoriasis. relevant issues to biological therapy persistence. Vestnik dermatologii i venerologii. 2016;5:32-38. (In Russ.).
Federal’nye klinicheskie rekomendacii. Dermatovenerologija 2015: Bolezni kozhi. Infekcii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Del. jekspress, 2016. (In Russ.).
Coates L, Murphy R and Helliwell P. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016;174:1174-1178. https://doi.org/10.1111/bjd.14667
Gisondi P, et al. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774-790. https://doi.org/10.1111/jdv.14114
Alexander Nast, Lasse Amelunxen, Matthias Augustin, Wolf- Henning Boehncke, Corinna Dressler, Matthew Gaskins, Peter Härle, Bernd Hoffstadt, Joachim Klaus, Joachim Koza, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Berthold Rzany, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Ralph von Kiedrowski, Tobias Weberschock. S3 Guideline for the treatment of psoriasis vulgaris, update — Short version part 1 — Systemic treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2018;16:645-669.
Abdulganieva DI, Bakulev AL, Belousova EA, Znamenskaya LF, Korotaeva TV, Kruglova LS, Kokhan MM, Lila AM, Khairutdinov VR, Khalif IL, Khobeish MM. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, crohn”s disease). Sovremennaya revmatologiya. 2018;12(3):4-18. (In Russ.).
Instrukcii po medicinskomu primeneniju preparatov. (In Russ.). https://grls.rosminzdrav.ru/grls.aspx
Bakulev AL, Samtsov AV, Kubanov AA, Khairutdinov VR, Kokhan MM, Artem’eva AV, Derbin SI, Chernyaeva EV, Ivanov RA. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext. Vestnik dermatologii i venerologii. 2019;95(3):54-64. (In Russ.). https://doi.org/10.25208/0042-4609-2019-95-3-54-64
Samtsov AV, Khairutdinov VR, Bakulev AL, Kubanov AA, Karamova AE, Artem’eva AV, Korotaeva TV. Efficacy and safety of bcd-085, a novel interleukin-17 inhibitor. results of phase ii clinical trial in patients with moderate-to-severe plaque psoriasis. Vestnik dermatologii i venerologii. 2017;5:52-63. (In Russ.). https://doi.org/10.25208/0042-4609-2017-93-5-52-63
Kubanov AA, Bakulev AL, Samtsov AV, Khairutdinov VR, Sokolovskiy EV, Kokhan MM, Artemyeva AV, Chernyaeva EV, Ivanov RA. Netakimab — new il inhibitor: 12-week results of phase iii clinical study bcd-085-7/planeta in patients with moderate-to-severe plaque psoriasis. Vestnik dermatologii i venerologii. 2019;95(2):15-28 (In Russ.).
Zhukov AS, Khairutdinov VR, Samtsov AV, Ivanov RA.The effect of netakimab therapy on the life quality of patients with plaque psoriasis. Jeffektivnaja farmakoterapija. 2019;15(35):8-12 (In Russ.).